-
1
-
-
20844460608
-
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine
-
Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193. (Pubitemid 39390442)
-
(2004)
Haematologica
, vol.89
, Issue.10
, pp. 1187-1193
-
-
Borgna-Pignatti, C.1
Rugolotto, S.2
De Stefano, P.3
Zhao, H.4
Cappellini, M.D.5
Del Vecchio, G.C.6
Romeo, M.A.7
Forni, G.L.8
Gamberini, M.R.9
Ghilardi, R.10
Piga, A.11
Cnaan, A.12
-
2
-
-
0030048681
-
Results of long-term iron-chelating therapy
-
Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
-
(1996)
Acta Haematol
, vol.95
, Issue.1
, pp. 26-36
-
-
Gabutti, V.1
Piga, A.2
-
3
-
-
0034631379
-
Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register
-
Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051-2052.
-
(2000)
Lancet
, vol.355
, Issue.9220
, pp. 2051-2052
-
-
Modell, B.1
Khan, M.2
Darlison, M.3
-
4
-
-
0028059813
-
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
-
Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573.
-
(1994)
N Engl J Med
, vol.331
, Issue.9
, pp. 567-573
-
-
Brittenham, G.M.1
Griffith, P.M.2
Nienhuis, A.W.3
-
5
-
-
34247271478
-
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective
-
DOI 10.2165/00019053-200725040-00005
-
Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007;25(4):329-342. (Pubitemid 46607383)
-
(2007)
PharmacoEconomics
, vol.25
, Issue.4
, pp. 329-342
-
-
Delea, T.E.1
Sofrygin, O.2
Thomas, S.K.3
Baladi, J.-F.4
Phatak, P.D.5
Coates, T.D.6
-
6
-
-
34547824328
-
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia
-
Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29(5):909-917.
-
(2007)
Clin Ther
, vol.29
, Issue.5
, pp. 909-917
-
-
Cappellini, M.D.1
Bejaoui, M.2
Agaoglu, L.3
-
7
-
-
52249085605
-
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload
-
Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9(13):2391-2402.
-
(2008)
Expert Opin Pharmacother
, vol.9
, Issue.13
, pp. 2391-2402
-
-
Cappellini, M.D.1
Taher, A.2
-
8
-
-
60749134100
-
Deferasirox in MDS patients with transfusion-caused iron overload: A phase-II study
-
Metzgeroth G, Dinter D, Schultheis B, et al. Deferasirox in MDS patients with transfusion-caused iron overload: a phase-II study. Ann Hematol. 2009;88(4):301-310.
-
(2009)
Ann Hematol
, vol.88
, Issue.4
, pp. 301-310
-
-
Metzgeroth, G.1
Dinter, D.2
Schultheis, B.3
-
9
-
-
33749991316
-
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major
-
Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006;91(10):1343-1351.
-
(2006)
Haematologica
, vol.91
, Issue.10
, pp. 1343-1351
-
-
Galanello, R.1
Piga, A.2
Forni, G.L.3
-
10
-
-
38049151217
-
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study
-
Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
-
(2008)
Eur J Haematol
, vol.80
, Issue.2
, pp. 168-176
-
-
Porter, J.1
Galanello, R.2
Saglio, G.3
-
11
-
-
33846012866
-
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
-
Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
-
(2007)
Br J Haematol
, vol.136
, Issue.3
, pp. 501-508
-
-
Vichinsky, E.1
Onyekwere, O.2
Porter, J.3
-
12
-
-
46049087344
-
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: Substudy of a randomized open-label phase II trial
-
Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label phase II trial. Acta Haematol. 2008;119(3):133-141.
-
(2008)
Acta Haematol
, vol.119
, Issue.3
, pp. 133-141
-
-
Vichinsky, E.1
Pakbaz, Z.2
Onyekwere, O.3
-
13
-
-
73149085204
-
Satisfaction and adherence significantly improves in beta-thalassemia and myelodysplastic syndromes treated with deferasirox (Exjade)
-
abstract
-
Porter JB, Bowden D, Ganser A, et al. Satisfaction and adherence significantly improves in beta-thalassemia and myelodysplastic syndromes treated with deferasirox (Exjade) [abstract]. Blood. 2008;112(11):1306.
-
(2008)
Blood
, vol.112
, Issue.11
, pp. 1306
-
-
Porter, J.B.1
Bowden, D.2
Ganser, A.3
-
14
-
-
33745774771
-
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload
-
Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873-880.
-
(2006)
Haematologica
, vol.91
, Issue.7
, pp. 873-880
-
-
Piga, A.1
Galanello, R.2
Forni, G.L.3
-
15
-
-
10744230223
-
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial
-
Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597-1602.
-
(2003)
Lancet
, vol.361
, Issue.9369
, pp. 1597-1602
-
-
Nisbet-Brown, E.1
Olivieri, N.F.2
Giardina, P.J.3
-
16
-
-
65349110837
-
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia
-
Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol. 2009;82(6):454-457.
-
(2009)
Eur J Haematol
, vol.82
, Issue.6
, pp. 454-457
-
-
Daar, S.1
Pathare, A.2
Nick, H.3
-
17
-
-
0029978555
-
Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy
-
Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996;88(2):705-713. (Pubitemid 26240403)
-
(1996)
Blood
, vol.88
, Issue.2
, pp. 705-713
-
-
Porter, J.B.1
Abeysinghe, R.D.2
Marshall, L.3
Hider, R.C.4
Singh, S.5
-
18
-
-
27644539382
-
Intracellular labile iron pools as direct targets of iron chelators: A fluorescence study of chelator action in living cells
-
Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106(9):3242-3250.
-
(2005)
Blood
, vol.106
, Issue.9
, pp. 3242-3250
-
-
Glickstein, H.1
El, R.B.2
Shvartsman, M.3
Cabantchik, Z.I.4
-
19
-
-
33750001927
-
Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences
-
Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108(9):3195-3203.
-
(2006)
Blood
, vol.108
, Issue.9
, pp. 3195-3203
-
-
Glickstein, H.1
El, R.B.2
Link, G.3
-
20
-
-
34250360747
-
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy
-
Otto-Duessel M, Aguilar M, Nick H, Moats R,Wood JC. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp Hematol. 2007;35(7):1069-1073.
-
(2007)
Exp Hematol
, vol.35
, Issue.7
, pp. 1069-1073
-
-
Otto-Duessel, M.1
Aguilar, M.2
Nick, H.3
Moats, R.4
Wood, J.C.5
-
21
-
-
33750282789
-
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil
-
DOI 10.1016/j.trsl.2006.05.005, PII S1931524406003161
-
Wood JC, Otto-Duessel M, Gonzalez I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res. 2006;148(5):272-280. (Pubitemid 44634299)
-
(2006)
Translational Research
, vol.148
, Issue.5
, pp. 272-280
-
-
Wood, J.C.1
Otto-Duessel, M.2
Gonzalez, I.3
Aguilar, M.I.4
Shimada, H.5
Nick, H.6
Nelson, M.7
Moats, R.8
-
22
-
-
77649296214
-
Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major
-
Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol. 2010;89(4):405-409.
-
(2010)
Ann Hematol
, vol.89
, Issue.4
, pp. 405-409
-
-
Pathare, A.1
Taher, A.2
Daar, S.3
-
23
-
-
77950617863
-
Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia
-
Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364-2371.
-
(2010)
Blood
, vol.115
, Issue.12
, pp. 2364-2371
-
-
Pennell, D.J.1
Porter, J.B.2
Cappellini, M.D.3
-
24
-
-
18044399191
-
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload
-
Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179.
-
(2001)
Eur Heart J
, vol.22
, Issue.23
, pp. 2171-2179
-
-
Anderson, L.J.1
Holden, S.2
Davis, B.3
-
25
-
-
33748361588
-
MRI detects myocardial iron in the human heart
-
Ghugre NR, Enriquez CM, Gonzalez I, Nelson MD Jr, Coates TD, Wood JC. MRI detects myocardial iron in the human heart. Magn Reson Med. 2006;56(3):681-686.
-
(2006)
Magn Reson Med
, vol.56
, Issue.3
, pp. 681-686
-
-
Ghugre, N.R.1
Enriquez, C.M.2
Gonzalez, I.3
Nelson Jr., M.D.4
Coates, T.D.5
Wood, J.C.6
-
26
-
-
72449177984
-
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major
-
Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
-
(2009)
Circulation
, vol.120
, Issue.20
, pp. 1961-1968
-
-
Kirk, P.1
Roughton, M.2
Porter, J.B.3
-
27
-
-
23744459788
-
MRI R2 and R2*mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients
-
DOI 10.1182/blood-2004-10-3982
-
Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-1465. (Pubitemid 41129616)
-
(2005)
Blood
, vol.106
, Issue.4
, pp. 1460-1465
-
-
Wood, J.C.1
Enriquez, C.2
Ghugre, N.3
Tyzka, J.M.4
Carson, S.5
Nelson, M.D.6
Coates, T.D.7
-
28
-
-
23044475721
-
Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy
-
Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112(4):535-543.
-
(2005)
Circulation
, vol.112
, Issue.4
, pp. 535-543
-
-
Wood, J.C.1
Otto-Duessel, M.2
Aguilar, M.3
-
29
-
-
77950425913
-
Deferasirox pharmacokinetics in patients with adequate versus inadequate response
-
Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009;114(19):4009-4013.
-
(2009)
Blood
, vol.114
, Issue.19
, pp. 4009-4013
-
-
Chirnomas, D.1
Smith, A.L.2
Braunstein, J.3
-
30
-
-
70449403619
-
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
-
Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147(5):752-759.
-
(2009)
Br J Haematol
, vol.147
, Issue.5
, pp. 752-759
-
-
Taher, A.1
Cappellini, M.D.2
Vichinsky, E.3
-
31
-
-
65349152022
-
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: The ESCALATOR study
-
Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458-465.
-
(2009)
Eur J Haematol
, vol.82
, Issue.6
, pp. 458-465
-
-
Taher, A.1
El-Beshlawy, A.2
Elalfy, M.S.3
-
32
-
-
0038481233
-
Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: Indication of close relation between myocardial iron content and chelatable iron pool
-
Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101(11):4632-4639.
-
(2003)
Blood
, vol.101
, Issue.11
, pp. 4632-4639
-
-
Jensen, P.D.1
Jensen, F.T.2
Christensen, T.3
Eiskjaer, H.4
Baandrup, U.5
Nielsen, J.L.6
-
33
-
-
0033760134
-
Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major
-
Telfer PT, Prestcott E, Holden S,Walker M, Hoffbrand AV,Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110(4):971-977.
-
(2000)
Br J Haematol
, vol.110
, Issue.4
, pp. 971-977
-
-
Telfer, P.T.1
Prestcott, E.2
Holden, S.3
Walker, M.4
Hoffbrand, A.V.5
Wonke, B.6
-
34
-
-
53449102748
-
Longitudinal analysis of heart and liver iron in thalassemia major
-
Noetzli LJ, Carson SM, Nord AS, Coates TD,Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973-2978.
-
(2008)
Blood
, vol.112
, Issue.7
, pp. 2973-2978
-
-
Noetzli, L.J.1
Carson, S.M.2
Nord, A.S.3
Coates, T.D.4
Wood, J.C.5
-
35
-
-
74049116227
-
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
-
Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466-475.
-
(2010)
Br J Haematol
, vol.148
, Issue.3
, pp. 466-475
-
-
Farmaki, K.1
Tzoumari, I.2
Pappa, C.3
Chouliaras, G.4
Berdoukas, V.5
-
36
-
-
38349157810
-
Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major
-
Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008;111(2):583-587.
-
(2008)
Blood
, vol.111
, Issue.2
, pp. 583-587
-
-
Cohen, A.R.1
Glimm, E.2
Porter, J.B.3
-
37
-
-
33646387405
-
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis
-
Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744.
-
(2006)
Blood
, vol.107
, Issue.9
, pp. 3738-3744
-
-
Pennell, D.J.1
Berdoukas, V.2
Karagiorga, M.3
-
38
-
-
34247103036
-
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance
-
Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884.
-
(2007)
Circulation
, vol.115
, Issue.14
, pp. 1876-1884
-
-
Tanner, M.A.1
Galanello, R.2
Dessi, C.3
|